The Prevalence of Musculoskeletal Disorders and its Relation with Fatigue and Occupational Burnout in the Staff of a Petrochemical Industry

Background: Occupational burnout is a sign of various fatigue states and can cause diseases like musculoskeletal disorders. The aim of this study was to determine the prevalence of musculoskeletal disorders and its relation with fatigue and occupational burnout in the staff of a petrochemical industry. Methods: The present study is a descriptive-analytical cross-sectional study conducted on 121 personnel working in a petrochemical industry in 2017. For data collection, the Multidimensional Fatigue Inventory (MFI) questionnaire, Nordic questionnaire, and Maslach Burnout questionnaire were used. Data were analyzed using SPSS 22 and the significance level was considered 0.05. Results: In general, 71.1% of the subjects suffered from at least one musculoskeletal disorder in their organs during the past year. There was no significant relation between musculoskeletal disorders and occupational burnout. Musculoskeletal disorders were significantly associated with decreased motivation (P=0.035), one of the fatigue domains. Musculoskeletal disorders were also significantly related with the type of occupation (P = 0.017). Conclusion: Musculoskeletal disorders are probably related with some fields of fatigue and burnout. Further studies should be done. Keywords: Musculoskeletal Disorders, Fatigue, Occupational Burnout, Petrochemical

Investigating the factors affecting the survival rate in patients with COVID-19 : A retrospective cohort study

Funding Information: Conflicts of Interest: None declared Funding: This study was financially supported by the Deputy of Research and Technology of Iran University of Medical Sciences, Tehran, Iran (Grant no. 17571).Peer reviewedPublisher PD

Assosition of diabetes and hypertension with the incidence of chronic kidney disease: Tehran Lipid and Glucose Study

زمینه و هدف: بیماری مزمن کلیوی اختلالی شایع است که با افزایش خطر بیماری های قلبی- عروقی، نارسایی کلیه و بروز عوارض دیگر همراه است. پیر شدن جمعیت و رشد شیوع جهانی دیابت و فشار خون بالا باعث افزایش شیوع بیماری مزمن کلیوی در سراسر جهان شده است. در این مطالعه ما به بررسی خطر دیابت، فشار خون بالا و برهمکنش آن ها بر بروز بیماری مزمن کلیوی پرداختیم. روش بررسی: این مطالعه یک مطالعه ثانویه بر داده های مطالعه قند و لیپید تهران است. در این مطالعه یک جمعیت 7342 نفری20 سال و بالاتر (8/46 مرد) مورد بررسی قرار گرفتند. ابتدا شرکت کنندگان به 4 گروه تقسیم شدند: گروه اول: شامل افراد بدون دیابت و بدون فشار خون بالا، گروه دوم: افراد دارای دیابت و بدون فشار خون بالا، گروه سوم: افراد بدون دیابت و دارای فشار خون بالا و گروه چهارم: افراد دارای هر دو عامل دیابت و فشار خون بالا بودند. سپس با استفاده از مدل رگرسیونی چند متغیره کاکس نسبت مخاطره هر گروه نسبت به گروه اول و با تعدیل متغیرهای سن، میزان پالایش گلومرولی، تحصیلات، وضعیت سیگار کشیدن، کلسترول سرم، تری گلیسیرید سرم، HDL سرم، نمایه توده بدنی و نمره گرایش محاسبه شد. یافته ها: در مردان گروه دوم، دیابت (بدون فشار خون بالا) با نسبت مخاطره (69/2-39/1)94/1 و در مردان گروه سوم فشار خون بالا (بدون دیابت) با نسبت مخاطره (96/1-27/1)58/1 هر دو عامل خطر بیماری مزمن کلیوی بودند. به همین ترتیب در زنان نیز نسبت مخاطره دیابت و فشار خون بالا به ترتیب (51/1-93/0)18/1 و (47/1-05/1)24/1 بود. همچنین در مردان و زنان دیابت با فشار خون بالا برهمکنش معنی داری در بروز بیماری مزمن کلیوی نداشتند. نتیجه گیری: یافته های این مطالعه نشان می دهد که فشار خون بالا بدون توجه به حضور یا عدم حضور دیابت در هر دو جنس یک عامل خطر مستقل در بروز بیماری مزمن کلیوی می باشد

Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial

Abstract Background The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve protection against emerging variants. Heterologous boosting is believed to result in more robust immune responses. This study investigated the safety and immunogenicity of the Razi Cov Pars vaccine (RCP) as a heterologous booster dose in people primed with Beijing Bio-Institute of Biological Products Coronavirus Vaccine (BBIBP-CorV). Methods We conducted a randomized, double-blind, active-controlled trial in adults aged 18 and over primarily vaccinated with BBIBP-CorV, an inactivated SARS-CoV-2 vaccine. Eligible participants were randomly assigned (1:1) to receive a booster dose of RCP or BBIBP-CorV vaccines. The primary outcome was neutralizing antibody activity measured by a conventional virus neutralization test (cVNT). The secondary efficacy outcomes included specific IgG antibodies against SARS-CoV-2 spike (S1 and receptor-binding domain, RBD) antigens and cell-mediated immunity. We measured humoral antibody responses at 2 weeks (in all participants) and 3 and 6 months (a subgroup of 101 participants) after the booster dose injection. The secondary safety outcomes were solicited and unsolicited immediate, local, and systemic adverse reactions. Results We recruited 483 eligible participants between December 7, 2021, and January 13, 2022. The mean age was 51.9 years, and 68.1% were men. Neutralizing antibody titers increased about 3 (geometric mean fold increase, GMFI = 2.77, 95% CI 2.26–3.39) and 21 (GMFI = 21.51, 95% CI 16.35–28.32) times compared to the baseline in the BBIBP-CorV and the RCP vaccine groups. Geometric mean ratios (GMR) and 95% CI for serum neutralizing antibody titers for RCP compared with BBIBP-CorV on days 14, 90, and 180 were 6.81 (5.32–8.72), 1.77 (1.15–2.72), and 2.37 (1.62–3.47) respectively. We observed a similar pattern for specific antibody responses against S1 and RBD. We detected a rise in gamma interferon (IFN-γ), tumor necrosis factor (TNF-α), and interleukin 2 (IL-2) following stimulation with S antigen, particularly in the RCP group, and the flow cytometry examination showed an increase in the percentage of CD3 + /CD8 + lymphocytes. RCP and BBIBP-CorV had similar safety profiles; we identified no vaccine-related or unrelated deaths. Conclusions BBIBP-CorV and RCP vaccines as booster doses are safe and provide a strong immune response that is more robust when the RCP vaccine is used. Heterologous vaccines are preferred as booster doses. Trial registration This study was registered with the Iranian Registry of Clinical Trial at www.irct.ir , IRCT20201214049709N4. Registered 29 November 2021

Additional file 1 of Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial

Additional file 1: Table S1. Geometric mean and 95% CI of specific antibody responses (AUC) to S1, RBD and Neutralizing antibody titer in the BBIBP-CorV and RCP groups over the predefined study time schedule. Tables S2-S4. Geometric mean, Geometric mean ratio, Geometric mean fold increase and Seroconversion and their 95% CI for Neutralizing antibodies, anti-RBD, and anti-S1 specific IgG antibodies in the BBIBP-CorV and Razi Cov Pars groups in the participants who received primary vaccination 3, 4, 5 and 6 month before booster dose over the predefined study time schedule. Table S5. Unsolicited adverse events with Not Related, Unlikely, Suspected/Possible, Probable and not assessable relationship to the BBIBP-CorV and Razi Cov Pars vaccines within one-month post-vaccination using ICD-10 code. Table S6. Unsolicited adverse events with probable/suspected relationship to the BBIBP-CorV and Razi Cov Pars vaccines using ICD-10 code. Figure S1. Gating strategy for CD3/CD4/CD8 and IFN-γ flow cytometry data analysis. Figure S2. Comparison of the baseline antibody levels and post-booster antibody responses among the four tested groups with different prime-boosting intervals (3, 4, 5 and 6 months before booster dose) on days 0 and 14